These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25470427)

  • 1. New binding face of C-type lectin-like domains.
    Fukuhara H; Furukawa A; Maenaka K
    Structure; 2014 Dec; 22(12):1694-1696. PubMed ID: 25470427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin.
    Nagae M; Morita-Matsumoto K; Kato M; Kaneko MK; Kato Y; Yamaguchi Y
    Structure; 2014 Dec; 22(12):1711-1721. PubMed ID: 25458834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
    Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The snake venom rhodocytin from Calloselasma rhodostoma- a clinically important toxin and a useful experimental tool for studies of C-type lectin-like receptor 2 (CLEC-2).
    Bruserud Ø
    Toxins (Basel); 2013 Apr; 5(4):665-74. PubMed ID: 23594438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombomodulation via CLEC-2 targeting.
    O'Callaghan CA
    Curr Opin Pharmacol; 2009 Apr; 9(2):90-5. PubMed ID: 19091630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.
    Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y
    J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A detailed proteomic analysis of rhodocytin-activated platelets reveals novel clues on the CLEC-2 signalosome: implications for CLEC-2 signaling regulation.
    Parguiña AF; Alonso J; Rosa I; Vélez P; González-López MJ; Guitián E; Eble JA; Loza MI; García Á
    Blood; 2012 Dec; 120(26):e117-26. PubMed ID: 23053573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel platelet activation receptor CLEC-2.
    Suzuki-Inoue K; Inoue O; Ozaki Y
    Platelets; 2011; 22(5):380-4. PubMed ID: 21714702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The crystal structure of the platelet activator aggretin reveals a novel (alphabeta)2 dimeric structure.
    Hooley E; Papagrigoriou E; Navdaev A; Pandey AV; Clemetson JM; Clemetson KJ; Emsley J
    Biochemistry; 2008 Jul; 47(30):7831-7. PubMed ID: 18597489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation.
    Chang CH; Chung CH; Hsu CC; Peng HC; Huang TF
    J Thromb Haemost; 2014 Apr; 12(4):540-9. PubMed ID: 24479713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of rhodocytin, a ligand for the platelet-activating receptor CLEC-2.
    Watson AA; Eble JA; O'Callaghan CA
    Protein Sci; 2008 Sep; 17(9):1611-6. PubMed ID: 18583525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of platelet aggregation by affinity captured rhodocytin from the Malayan pit viper Calloselasma rhodostoma.
    Feickert MK; Sanz-Soler R; Niland S; König S; Eble JA; Obermann WMJ
    Toxicon; 2023 Mar; 225():107058. PubMed ID: 36806336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation.
    Suzuki-Inoue K
    J Biochem; 2011 Aug; 150(2):127-32. PubMed ID: 21693546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal cells activate the platelet receptor CLEC-2 through podoplanin.
    Christou CM; Pearce AC; Watson AA; Mistry AR; Pollitt AY; Fenton-May AE; Johnson LA; Jackson DG; Watson SP; O'Callaghan CA
    Biochem J; 2008 Apr; 411(1):133-40. PubMed ID: 18215137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of the interaction of the snake venom rhodocytin with the platelet receptor CLEC-2.
    Watson AA; O'Callaghan CA
    Toxins (Basel); 2011 Aug; 3(8):991-1003. PubMed ID: 22069753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RACK1 associates with CLEC-2 and promotes its ubiquitin-proteasome degradation.
    Ruan Y; Guo L; Qiao Y; Hong Y; Zhou L; Sun L; Wang L; Zhu H; Wang L; Yun X; Xie J; Gu J
    Biochem Biophys Res Commun; 2009 Dec; 390(2):217-22. PubMed ID: 19785988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2.
    Watson AA; Brown J; Harlos K; Eble JA; Walter TS; O'Callaghan CA
    J Biol Chem; 2007 Feb; 282(5):3165-72. PubMed ID: 17132623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The platelet receptor CLEC-2 is active as a dimer.
    Watson AA; Christou CM; James JR; Fenton-May AE; Moncayo GE; Mistry AR; Davis SJ; Gilbert RJ; Chakera A; O'Callaghan CA
    Biochemistry; 2009 Nov; 48(46):10988-96. PubMed ID: 19824697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional conservation of CLEC-2 with the species-specific regulation of transcript expression in evolution.
    Wang L; Ren S; Zhu H; Zhang D; Hao Y; Ruan Y; Zhou L; Lee C; Qiu L; Yun X; Xie J
    Glycoconj J; 2012 Aug; 29(5-6):335-45. PubMed ID: 22740230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lebectin and lebecetin, two C-type lectins from snake venom, inhibit alpha5beta1 and alphaV-containing integrins.
    Sarray S; Delamarre E; Marvaldi J; El Ayeb M; Marrakchi N; Luis J
    Matrix Biol; 2007 May; 26(4):306-13. PubMed ID: 17300927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.